SCHEMBL421283

SCHEMBL421283

CC(CCOCCO)C(=O)Sc1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
HPGD P15428 4/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 6/20 0.37
RAB9A P51151 3/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
ALOX15 P16050 1/20 0.36
TP53 P04637 1/20 0.36
GRM2 Q14416 1/20 0.35
MAPT P10636 2/20 0.35
PKM P14618 1/20 0.35
POLB P06746 1/20 0.34
MAPK10 P53779 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13030806 0.86 LMNA (0.39) LMNASMN1; SMN2HPGDKMT2AMEN1
SCHEMBL421227 0.77 ALDH1A1 (0.44) LMNASMN1; SMN2HPGDKMT2AMEN1
SCHEMBL464425 0.74 HPGD (0.49) LMNASMN1; SMN2HPGDKMT2AMEN1
SCHEMBL7102145 0.70 HPGD (0.42) LMNASMN1; SMN2HPGDKMT2AMEN1
SCHEMBL464396 0.68 LMNA (0.41) LMNASMN1; SMN2HPGDKMT2AMEN1
SCHEMBL14984823 0.68 EHMT2 (0.48) LMNAHPGDKMT2AMEN1TSHR
SCHEMBL30833293 0.68 EHMT2 (0.48) LMNAHPGDKMT2AMEN1TSHR
SCHEMBL15140934 0.67 EHMT2 (0.47) LMNASMN1; SMN2HPGDKMT2AMEN1
SCHEMBL10327179 0.67 EHMT2 (0.47) LMNASMN1; SMN2HPGDKMT2AMEN1
SCHEMBL18369713 0.67 EHMT2 (0.47) LMNASMN1; SMN2HPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329876-B2 Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith NEKTAR THERAPEUTICS (US) 2012-12-11 US disclosed
US-20120065330-A1 Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith NEKTAR THERAPEUTICS (US) 2012-03-15 US disclosed
US-8071678-B2 Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith NEKTAR THERAPEUTICS (US) 2011-12-06 US disclosed
US-20110065862-A1 Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith NEKTAR THERAPEUTICS (US) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065330-A1 Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith PCTP, CETP, NGLY1 LMNA 2605/4885SMN1; SMN2 4702/4885HPGD 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.